Board of Appeal rebuked by General Court for ruling of its own motion on earlier mark's genuine use

European Union

In invalidity proceedings between Glaxo Group and Celon Pharma, the EU General Court has held that the Board of Appeal of the EUIPO did not have the competence to rule of its own motion on the earlier mark's genuine use.

Unlock unlimited access to all WTR content